Translational -omics: Future potential and current challenges in precision medicine.

Rapid advances in computational science and biotechnology are paving the way for precision medicine - a vision in next-generation healthcare that promises to provide a care package uniquely tailored to each individual's molecular make-up. Until relatively recently, the focus has been firmly centred around the genome; however, over the past two decades there has been a surge in the study of molecular activity within other biological domains (proteome/transcriptome/metabolome) involved in health and pathogenesis. The term '-omics' is broadly applied to these disciplines and 'translational -omics' refers to clinical utilisation of data derived from these scientific approaches. Translational -omics represents the cornerstone of the precision medicine initiative and offers positively disruptive solutions in global healthcare from a humanitarian, scientific and economic standpoint. However, there are unique challenges anticipated for all stakeholders within the precision medicine community, and addressing these early on in the adoption of precision approaches is critical. Herein, we outline the potential for translational -omics in precision medicine, highlight key roadblocks to successful implementation and propose potential solutions to current and expected problems.

[1]  L. Stein.  The case for cloud computing in genome informatics , 2010, Genome Biology.

[2]  L. Kenny,et al.  ‘Omic’ technologies: genomics, transcriptomics, proteomics and metabolomics , 2011 .

[3]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[4]  D. Pe’er,et al.  An Integrated Approach to Uncover Drivers of Cancer , 2010, Cell.

[5]  Krishna Chinthapalli.  The hackers holding hospitals to ransom , 2017, British Medical Journal.

[6]  J. Irwin,et al.  Docking and chemoinformatic screens for new ligands and targets. , 2009, Current opinion in biotechnology.

[7]  S. Rosenbaum,et al.  Who should determine when health care is medically necessary? , 1999, The New England journal of medicine.

[8]  Ara Darzi,et al.  Preparing for precision medicine. , 2012, The New England journal of medicine.

[9]  G. Sauter,et al.  Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer. , 2010, Lung cancer.

[10]  Tarek Mekhail,et al.  Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[11]  T. Payne.  Computer decision support systems. , 2000, Chest.

[12]  Bert Vogelstein,et al.  The role of companion diagnostics in the development and use of mutation-targeted cancer therapies , 2006, Nature Biotechnology.

[13]  Michael N. Leuenberger,et al.  Quantum computing in molecular magnets , 2000, Nature.

[14]  A. Lokshin,et al.  Biomarker Testing for Ovarian Cancer: Clinical Utility of Multiplex Assays , 2013, Molecular Diagnosis & Therapy.

[15]  K. Steele,et al.  Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. , 2016, The Lancet. Oncology.

[16]  R. Weinshilboum,et al.  Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine , 2016, Nature Reviews Drug Discovery.

[17]  S. Plevritis,et al.  Identification of ovarian cancer driver genes by using module network integration of multi-omics data , 2013, Interface Focus.

[18]  M. Lawrence,et al.  SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors , 2018, Nature Medicine.

[19]  Borja Sotomayor,et al.  Cloud-based bioinformatics workflow platform for large-scale next-generation sequencing analyses , 2014, J. Biomed. Informatics.

[20]  Ludmila V. Danilova,et al.  Detection and localization of surgically resectable cancers with a multi-analyte blood test , 2018, Science.

[21]  Peter A. Chow-White,et al.  Knowledge, attitudes, and values among physicians working with clinical genomics: a survey of medical oncologists , 2017, Human Resources for Health.

[22]  Jeremy W Tomlinson,et al.  Regulation—the real threat to clinical research , 2008, BMJ : British Medical Journal.

[23]  A. Lipman.  Drug Repurposing and Repositioning: Workshop Summary , 2015 .

[24]  Pam Carter,et al.  The social licence for research: why care.data ran into trouble , 2015, Journal of Medical Ethics.

[25]  E. Diener,et al.  Culture and well-being , 2009 .

[26]  G. Omenn,et al.  Evolution of Translational Omics: Lessons Learned and the Path Forward , 2013 .